Trials / Completed
CompletedNCT03586427
Zelquistinel in the Treatment of Major Depressive Disorder
A Double-Blind, Placebo-Controlled, Fixed-Dose Study of AGN-241751 in Adult Participants With Major Depressive Disorder
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- Syndeio Biosciences, Inc · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy at 1 day post initial oral dose of zelquistinel (AGN-241751) compared with placebo in participants with Major Depressive Disorder (MDD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AGN-241751 | AGN-241751 administered orally as a single tablet |
| DRUG | Placebo | Placebo administered orally as a single tablet |
Timeline
- Start date
- 2018-06-13
- Primary completion
- 2019-07-22
- Completion
- 2019-08-21
- First posted
- 2018-07-13
- Last updated
- 2026-03-31
- Results posted
- 2022-08-02
Locations
25 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03586427. Inclusion in this directory is not an endorsement.